August 13, 2025 — Leads & Copy — Satellos Bioscience Inc. announced its financial results and corporate highlights for the second quarter ended June 30, 2025. The company is developing medicines to treat degenerative muscle diseases.
Satellos Co-Founder and CEO Frank Gleeson said the company is excited by the clean safety profile and promising functional improvements with SAT-3247 in its Phase 1a/1b study.
SAT-3247 Clinical Progress
Satellos announced positive Phase 1b results from a 28-day open-label study in five adult male patients with DMD on May 22, 2025. SAT-3247 was safe and well tolerated in all participants.
Grip strength showed an approximate doubling across the 5 participants. Patients also demonstrated an approximate average increase in force-vital capacity of 5%.
Satellos received approval and plans to initiate SAT-3247-LT-001 in Q3 2025. Interim 3-month results are expected prior to year-end. Satellos also plans to expand the protocol to include additional patients.
Satellos is on track to submit an IND application to the FDA and CTAs in other countries in Q3 2025 to enable initiation of a global Phase 2 randomized, placebo-controlled, proof-of-concept trial in pediatric patients with DMD.
Financial Results
Satellos had cash and cash equivalents and short-term investments of $38.2 million as of June 30, 2025, compared with $48.5 million at Dec. 31, 2024. For the three months ended June 30, 2025, Satellos reported a net loss of $5.6 million ($0.03 loss per share), compared to a net loss of $4.4 million ($0.04 loss per share) for the three months ended June 30, 2024.
R&D expenses increased to $4.4 million for the three months ended June 30, 2025, compared to $3.6 million for the three months ended June 30, 2024. G&A expenses increased to $1.9 million for the three months ended June 30, 2025, as compared to $1.3 million for the three months ended June 30, 2024.
SAT-3247 is a proprietary, oral, small molecule drug being developed by Satellos as a novel treatment to regenerate skeletal muscle that is lost in Duchenne muscular dystrophy and other degenerative or injury conditions.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases.
Contact: Frank Gleeson, Satellos Co-Founder and Chief Executive Officer.
Source: Satellos Bioscience Inc.
